455 Treg-associated ICOS as a possible biomarker for PD-1 therapy resistance in melanoma patients

Shannon N Geels, Alexander Moshensky, Rachel S Sousa, Claire Murat, Matías A. Bustos, Benjamin L. Walker, Rima Singh, Thuy B. Tran, Stacey N. Harbour, Giselle Gutierrez, Ji Won Hwang, Thorsten R. Mempel, Casey T. Weaver, Qing Nie, Dave S.�b. Hoon, Anand K. Ganesan, Shivashankar Othy, Francesco MarangoniRegular 2025 · DOI

Abstract

PD-1 immunotherapy has transformed melanoma care, but resistance remains common. This study identifies a "backfire" mechanism where PD-1 blockade activates CD8+ T cells to produce IL-2, which inadvertently supports immunosuppressive Regulatory T cells (Tregs) via the ICOS pathway. We demonstrate that ICOS expression on Tregs is a potential biomarker for resistance and that blocking the ICOS pathway can enhance therapeutic efficacy.

Introduction: The Challenge of PD-1 Resistance

While PD-1 checkpoint inhibitors have revolutionized metastatic melanoma treatment, many patients fail to achieve durable responses. A primary obstacle is the accumulation of Tregs within the tumor microenvironment. These cells suppress anti-tumor immunity, effectively acting as "brakes" that counteract the therapy's intended "gas." This research investigates the molecular drivers of Treg accumulation during PD-1 blockade to identify resistance biomarkers and novel combination strategies.

Methods

The study utilized a multi-scale approach combining mouse models and human clinical data:

  • Mouse Models: The immunogenic D4M-S melanoma model and transgenic mice were used to track immune cell dynamics.
  • Intravital Imaging: Multi-photon intravital microscopy (MP-IVM) visualized real-time T cell interactions in living tumors.
  • Human Data Analysis: Retrospective analysis of melanoma patient RNA-seq and immunofluorescence data.
  • Prospective Clinical Cohort: Longitudinal profiling of T cells in blood and lymph nodes from 20 therapy-naive stage III-IV melanoma patients before and during PD-1 blockade.

Key Results: Treg Accumulation and the ICOS Pathway

A central finding is that αPD-1 therapy leads to a significant increase in tumor-associated Tregs. In the D4M-S mouse model, a 2.6-fold increase in Treg density was observed ($p=0.001$). This phenomenon was mirrored in human clinical data across multiple studies, where a majority of patients showed increased Treg presence following treatment.

Treg accumulation in mouse models and human patients following αPD-1 therapy.

The mechanism is indirect: αPD-1 activates CD8+ T cells to secrete IL-2, which then fuels Treg survival and accumulation through the ICOS protein. This "crosstalk" creates a feedback loop that limits the efficacy of the checkpoint inhibitor.

Enhancing Efficacy via ICOSL Blockade

To overcome this resistance, the researchers tested the combination of αPD-1 with an ICOSL blockade. In mouse models, interrupting the ICOS signaling pathway significantly improved tumor control compared to αPD-1 monotherapy.

Experimental overview and tumor volume curves (Panel K) demonstrating improved control with combined αPD-1 and αICOSL treatment.

Furthermore, preliminary clinical data suggests that high ICOS expression on Tregs prior to treatment correlates with poor responsiveness to PD-1 blockade, highlighting its potential as a predictive biomarker.

Conclusion and Future Directions

This study elucidates a critical mechanism of immunotherapy resistance: the inadvertent support of Tregs by activated CD8+ T cells via the IL-2/ICOS axis. ICOS expression on Tregs serves as a promising biomarker for identifying patients likely to resist PD-1 monotherapy. Future work with larger patient cohorts will aim to validate ICOS as a clinical tool and explore the potential of ICOS-targeted combination therapies to prevent resistance and hyperprogression.

Summary updated

Abstract

Figure 1 Interruption of the intratumor CD8+ T cell:Treg crosstalk through ICOSL blockade improves the efficacy of PD-1 immunotherapy.Data summary describing mechanism of intratumor support to Tregs through CD8 IL-2 production during PD-1 blockade
BibTeX
@inproceedings{geels2025treg,
  author = {Shannon N Geels and Alexander Moshensky and Rachel S Sousa and Claire Murat and Matías A. Bustos and Benjamin L. Walker and Rima Singh and Thuy B. Tran and Stacey N. Harbour and Giselle Gutierrez and Ji Won Hwang and Thorsten R. Mempel and Casey T. Weaver and Qing Nie and Dave S.�B. Hoon and Anand K. Ganesan and Shivashankar Othy and Francesco Marangoni},
  title = {{455 Treg-associated ICOS as a possible biomarker for PD-1 therapy resistance in melanoma patients}},
  booktitle = {Regular},
  year = {2025},
  doi = {10.1136/jitc-2025-sitc2025.0455},
}
Figure